{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:23:41Z","timestamp":1792445021534,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Science & Technology Department of Sichuan Province","doi-asserted-by":"crossref","award":["2024YFFK0025"],"award-info":[{"award-number":["2024YFFK0025"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"crossref"}]},{"name":"1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University","award":["23HXFH025"],"award-info":[{"award-number":["23HXFH025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04588-6","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:42:19Z","timestamp":1775047339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["BRAF\/MEK inhibitors for redifferentiation in patients with radioiodine refractory thyroid cancer: A systematic review and Meta-Analysis"],"prefix":"10.1007","volume":"91","author":[{"given":"Kexin","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuewen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-0528","authenticated-orcid":false,"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"4588_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2023.26348","volume":"331","author":"L Boucai","year":"2024","unstructured":"L. Boucai, M. Zafereo, M.E. Cabanillas, Thyroid cancer: A review. JAMA 331, 425\u2013435 (2024). https:\/\/doi.org\/10.1001\/jama.2023.26348","journal-title":"JAMA"},{"key":"4588_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12020-018-1713-2","volume":"63","author":"D Albano","year":"2019","unstructured":"D. Albano, M.B. Panarotto, R. Durmo, C. Rodella, F. Bertagna, R. Giubbini, Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer. Endocrine. 63, 79\u201386 (2019). https:\/\/doi.org\/10.1007\/s12020-018-1713-2","journal-title":"Endocrine"},{"key":"4588_CR3","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli et al., Long-Term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892\u20132899 (2006). https:\/\/doi.org\/10.1210\/jc.2005-2838","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4588_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.clon.2004.06.018","volume":"16","author":"SC Short","year":"2004","unstructured":"S.C. Short, A. Suovuori, G. Cook, G. Vivian, C. Harmer, A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin. Oncol. (R Coll. Radiol). 16, 569\u2013574 (2004). https:\/\/doi.org\/10.1016\/j.clon.2004.06.018","journal-title":"Clin. Oncol. (R Coll. Radiol)"},{"key":"4588_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1365-2265.2006.02515.x","volume":"64","author":"YY Liu","year":"2006","unstructured":"Y.Y. Liu, van der G. Pluijm, M. Karperien, M.P.M. Stokkel, A.M. Pereira, J. Morreau et al., Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. Clin. Endocrinol. (Oxf). 64, 617\u2013624 (2006). https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02515.x","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4588_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","volume":"20","author":"I Landa","year":"2024","unstructured":"I. Landa, M.E. Cabanillas, Genomic alterations in thyroid cancer: biological and clinical insights. Nat. Rev. Endocrinol. 20, 93\u2013110 (2024). https:\/\/doi.org\/10.1038\/s41574-023-00920-6","journal-title":"Nat. Rev. Endocrinol."},{"key":"4588_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pharmthera.2012.06.007","volume":"135","author":"T Kogai","year":"2012","unstructured":"T. Kogai, G.A. Brent, The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol. Ther. 135, 355\u2013370 (2012). https:\/\/doi.org\/10.1016\/j.pharmthera.2012.06.007","journal-title":"Pharmacol. Ther."},{"key":"4588_CR8","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.7150\/thno.57689","volume":"11","author":"JM Oh","year":"2021","unstructured":"J.M. Oh, B.C. Ahn, Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics. 11, 6251\u20136277 (2021). https:\/\/doi.org\/10.7150\/thno.57689","journal-title":"Theranostics"},{"key":"4588_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-06-1753","volume":"13","author":"D Liu","year":"2007","unstructured":"D. Liu, S. Hu, P. Hou, D. Jiang, S. Condouris, M. Xing, Suppression of BRAF\/MEK\/MAP kinase pathway restores expression of Iodide-Metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin. Cancer Res. 13, 1341\u20131349 (2007). https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1753","journal-title":"Clin. Cancer Res."},{"key":"4588_CR10","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.3390\/cancers13225861","volume":"13","author":"M Faria","year":"2021","unstructured":"M. Faria, R. Domingues, M.J. Bugalho, P. Matos, A.L. Silva, MAPK Inhibition requires active RAC1 signaling to effectively improve iodide uptake by thyroid follicular cells. Cancers (Basel). 13, 5861 (2021). https:\/\/doi.org\/10.3390\/cancers13225861","journal-title":"Cancers (Basel)"},{"key":"4588_CR11","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1172\/JCI46382","volume":"121","author":"D Chakravarty","year":"2011","unstructured":"D. Chakravarty, E. Santos, M. Ryder, J.A. Knauf, X.-H. Liao, B.L. West et al., Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest. 121, 4700\u20134711 (2011). https:\/\/doi.org\/10.1172\/JCI46382","journal-title":"J. Clin. Invest."},{"key":"4588_CR12","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1210\/jc.2014-3023","volume":"100","author":"M Ruan","year":"2015","unstructured":"M. Ruan, M. Liu, Q. Dong, L. Chen, Iodide- and glucose-handling gene expression regulated by Sorafenib or Cabozantinib in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 100, 1771\u20131779 (2015). https:\/\/doi.org\/10.1210\/jc.2014-3023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4588_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"A.L. Ho, R.K. Grewal, R. Leboeuf, E.J. Sherman, D.G. Pfister, D. Deandreis et al., Selumetinib-Enhanced radioiodine uptake in advanced thyroid cancer. N Engl. J. Med. 368, 623\u2013632 (2013). https:\/\/doi.org\/10.1056\/NEJMoa1209288","journal-title":"N Engl. J. Med."},{"key":"4588_CR14","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"J.A. Sterne, M.A. Hern\u00e1n, B.C. Reeves, J. Savovi\u0107, N.D. Berkman, M. Viswanathan et al., ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 355, i4919 (2016). https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"4588_CR15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","volume":"21","author":"SM Rothenberg","year":"2015","unstructured":"S.M. Rothenberg, D.G. McFadden, E.L. Palmer, G.H. Daniels, L.J. Wirth, Redifferentiation of Iodine-Refractory BRAF V600E-Mutant metastatic papillary thyroid cancer with Dabrafenib. Clin. Cancer Res. 21, 1028\u20131035 (2015). https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2915","journal-title":"Clin. Cancer Res."},{"key":"4588_CR16","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1210\/jc.2018-01478","volume":"104","author":"LA Dunn","year":"2019","unstructured":"L.A. Dunn, E.J. Sherman, S.S. Baxi, V. Tchekmedyian, R.K. Grewal, S.M. Larson et al., Vemurafenib redifferentiation of BRAF Mutant, RAI-Refractory thyroid cancers. J. Clin. Endocrinol. Metab. 104, 1417\u20131428 (2019). https:\/\/doi.org\/10.1210\/jc.2018-01478","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4588_CR17","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","volume":"28","author":"M Weber","year":"2022","unstructured":"M. Weber, D. Kersting, B. Riemann, T. Brandenburg, D. F\u00fchrer-Sakel, F. Gr\u00fcnwald et al., Enhancing radioiodine incorporation into radioiodine-Refractory thyroid cancer with MAPK Inhibition (ERRITI): A Single-Center prospective Two-Arm study. Clin. Cancer Res. 28, 4194\u20134202 (2022). https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0437","journal-title":"Clin. Cancer Res."},{"key":"4588_CR18","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1089\/thy.2023.0240","volume":"33","author":"S Leboulleux","year":"2023","unstructured":"S. Leboulleux, D. Benisvy, D. Taieb, M. Attard, C. Bournaud, M. Terroir-Cassou-Mounat et al., MERAIODE: A phase II redifferentiation trial with Trametinib and 131I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer. Thyroid. 33, 1124\u20131129 (2023). https:\/\/doi.org\/10.1089\/thy.2023.0240","journal-title":"Thyroid"},{"key":"4588_CR19","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","volume":"29","author":"S Leboulleux","year":"2023","unstructured":"S. Leboulleux, C. Do Cao, S. Zerdoud, M. Attard, C. Bournaud, L. Lacroix et al., A phase II redifferentiation trial with Dabrafenib-Trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-Mutated differentiated thyroid cancer. Clin. Cancer Res. 29, 2401\u20132409 (2023). https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0046","journal-title":"Clin. Cancer Res."},{"key":"4588_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/thy.2022.0707","volume":"33","author":"J Wadsley","year":"2023","unstructured":"J. Wadsley, G. Ainsworth, A.B. Coulson, K. Garcez, L. Moss, K. Newbold et al., Results of the SEL-I-METRY phase II trial on resensitization of advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. Thyroid. 33, 1119\u20131123 (2023). https:\/\/doi.org\/10.1089\/thy.2022.0707","journal-title":"Thyroid"},{"key":"4588_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/thy.2023.0456","volume":"34","author":"D Toro-Tobon","year":"2024","unstructured":"D. Toro-Tobon, J.C. Morris, C. Hilger, C. Peskey, J.M. Durski, M. Ryder, Clinical outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers. Thyroid. 34, 70\u201381 (2024). https:\/\/doi.org\/10.1089\/thy.2023.0456","journal-title":"Thyroid"},{"key":"4588_CR22","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1172\/JCI89067","volume":"126","author":"J Nagarajah","year":"2016","unstructured":"J. Nagarajah, M. Le, J.A. Knauf, G. Ferrandino, C. Montero-Conde, N. Pillarsetty et al., Sustained ERK Inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J. Clin. Invest. 126, 4119\u20134124 (2016). https:\/\/doi.org\/10.1172\/JCI89067","journal-title":"J. Clin. Invest."},{"key":"4588_CR23","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, J. Sosman et al., Combined BRAF and MEK Inhibition in melanoma with BRAF V600 mutations. N Engl. J. Med. 367, 1694\u20131703 (2012). https:\/\/doi.org\/10.1056\/NEJMoa1210093","journal-title":"N Engl. J. Med."},{"key":"4588_CR24","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","volume":"28","author":"GV Long","year":"2017","unstructured":"G.V. Long, K.T. Flaherty, D. Stroyakovskiy, H. Gogas, E. Levchenko, de F. Braud et al., Dabrafenib plus Trametinib versus Dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann. Oncol. 28, 1631\u20131639 (2017). https:\/\/doi.org\/10.1093\/annonc\/mdx176","journal-title":"Ann. Oncol."},{"key":"4588_CR25","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/thy.2022.0115","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"N.L. Busaidy, B. Konda, L. Wei, L.J. Wirth, C. Devine, G.A. Daniels et al., Dabrafenib versus Dabrafenib\u2009+\u2009Trametinib in BRAF-Mutated radioactive iodine refractory differentiated thyroid cancer: results of a Randomized, phase 2, Open-Label multicenter trial. Thyroid. 32, 1184\u20131192 (2022). https:\/\/doi.org\/10.1089\/thy.2022.0115","journal-title":"Thyroid"},{"key":"4588_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/thy.2021.0565","volume":"32","author":"V Tchekmedyian","year":"2022","unstructured":"V. Tchekmedyian, L. Dunn, E. Sherman, S.S. Baxi, R.K. Grewal, S.M. Larson et al., Enhancing radioiodine incorporation in BRAF-Mutant, radioiodine-Refractory thyroid cancers with Vemurafenib and the Anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial. Thyroid. 32, 273\u2013282 (2022). https:\/\/doi.org\/10.1089\/thy.2021.0565","journal-title":"Thyroid"},{"key":"4588_CR27","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1007\/s00259-024-06747-1","volume":"51","author":"D Weiler","year":"2024","unstructured":"D. Weiler, M.D.S. P\u00e9rez Lago, Successful radioiodine redifferentiation with Selpercatinib in RET fusion-positive papillary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging. 51, 3467\u20133468 (2024). https:\/\/doi.org\/10.1007\/s00259-024-06747-1","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"4588_CR28","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1056\/NEJMc2023094","volume":"383","author":"L Groussin","year":"2020","unstructured":"L. Groussin, J. Clerc, O. Huillard, Larotrectinib-Enhanced radioactive iodine uptake in advanced thyroid cancer. N Engl. J. Med. 383, 1686\u20131687 (2020). https:\/\/doi.org\/10.1056\/NEJMc2023094","journal-title":"N Engl. J. Med."},{"key":"4588_CR29","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1097\/RLU.0000000000004475","volume":"48","author":"H-P Chan","year":"2023","unstructured":"H.-P. Chan, I.-F. Chen, F.-R. Tsai, C.-H. Kao, D.H.-Y. Shen, Reversing Flip-Flop phenomenon of 131 I and glucose avidity in RET-Fusion positive Radioiodine-Refractory thyroid cancer lesions after treatment of Pralsetinib. Clin. Nucl. Med. 48, e147\u2013e148 (2023). https:\/\/doi.org\/10.1097\/RLU.0000000000004475","journal-title":"Clin. Nucl. Med."},{"key":"4588_CR30","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1038\/s41467-021-26343-3","volume":"12","author":"W Pu","year":"2021","unstructured":"W. Pu, X. Shi, P. Yu, M. Zhang, Z. Liu, L. Tan et al., Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma. Nat. Commun. 12, 6058 (2021). https:\/\/doi.org\/10.1038\/s41467-021-26343-3","journal-title":"Nat. Commun."},{"key":"4588_CR31","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1210\/jc.2016-2620","volume":"101","author":"S Kakarmath","year":"2016","unstructured":"S. Kakarmath, H.T. Heller, C.A. Alexander, E.S. Cibas, J.F. Krane, J.A. Barletta et al., Clinical, Sonographic, and pathological characteristics of RAS-Positive versus BRAF-Positive thyroid carcinoma. J. Clin. Endocrinol. Metab. 101, 4938\u20134944 (2016). https:\/\/doi.org\/10.1210\/jc.2016-2620","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4588_CR32","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network, Integrated genomic characterization of papillary thyroid carcinoma. Cell. 159, 676\u2013690 (2014). https:\/\/doi.org\/10.1016\/j.cell.2014.09.050","journal-title":"Cell"},{"key":"4588_CR33","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","volume":"17","author":"MS Brose","year":"2016","unstructured":"M.S. Brose, M.E. Cabanillas, E.E.W. Cohen, L.J. Wirth, T. Riehl, H. Yue et al., Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 17, 1272\u20131282 (2016). https:\/\/doi.org\/10.1016\/S1470-2045(16)30166-8","journal-title":"Lancet Oncol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04588-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04588-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04588-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:42:20Z","timestamp":1775047340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04588-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4588"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04588-6","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Additional ethical approval was not required for this systematic review and meta-analysis, as it involved the synthesis of data from previously published studies, each of which had already obtained ethical approval from their respective institutional review boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"121"}}